Akademik Veri Yönetim Sistemi
32nd European Congress on Obesity (ECO 2025), Malaga, İspanya, 11 - 14 Mayıs 2025, ss.41-42, (Özet Bildiri)
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is the leading cause of liver-related morbidity and mortality, affecting more than 30% of the general population. MASLD is also a significant risk factor for major adverse cardiovascular events, and its prevalence increases with the presence of cardiovascular risk factors. This study aimed to determine the prevalence of MASLD and the risk of hepatic fibrosis among patients with cardiometabolic risk factors.
Methods: This nationwide study is a cross-sectional analysis of a prospective cohort of patients with at least one cardiometabolic risk factor in 34 cities and 44 internal medicine outpatient units representing all statistical regions of Türkiye. MASLD was defined as hepatic steatosis on abdominal ultrasonography with at least one cardiometabolic risk factor (i.e., high blood pressure, glucose, body weight, or blood lipids). The risk of hepatic fibrosis was noninvasively assessed with the Fibrosis-4 (FIB-4) index, and a score equal or over 1.3 was accepted as a high risk of liver fibrosis. People equal and over 18 years with at least one cardiometabolic risk factor were enrolled consecutively. The exclusion criteria were the presence of pregnancy, acute inflammation, malignancy, bariatric surgery, and the history of the specific causes of chronic liver disease such as high alcohol intake, viral hepatitis, and depot diseases.
Results: A total of 14371 patients (61.4% female, mean age 51.3 ± 14.4 years, body mass index 31.4 ± 6.0 kg/m2) with cardiometabolic risk factors were enrolled (Table). The overall prevalence of MASLD was 75.7%. The prevalence of high FIB-4 risk among patients with MASLD was 16.7%. The prevalence of MASLD and high FIB-4 score increased along with the increasing numbers of cardiovascular risk factors (Figure 1a, 1b). In the multivariable model, age (OR: 1.113, 95%CI: 1.106-1.120), female sex (OR: 1.540, 95%CI: 1.360-1.745), diabetes mellitus (OR: 1.229, 95%CI: 1.084-1.393) and hypertension (OR: 1.145, 95%CI: 1.007-1.302) were the significant independent associates of high fibrosis risk (Figure-2).
Conclusion: This nationwide report shows that MASLD is highly prevalent in subjects with cardiometabolic risk. The risk of MASLD increases along with the number of cardiometabolic risk factors. Among the population with MASLD, much attention should be given to those with older age, female sex, diabetes mellitus, or hypertension, as they are the ones with the highest risk of liver fibrosis.